

Review article

Disorder, not just state of risk: meta-analysis of functioning and quality of life in people at high risk of psychosis

Paolo Fusar-Poli,* Matteo Rocchetti,* Alberto Sardella, Alessia Avila, Martina Brandizzi, Edgardo Caverzasi, Pierluigi Politi, Stephan Ruhrmann and Philip McGuire

Background

The nosology of the psychosis high-risk state is controversial. Traditionally conceived as an 'at risk' state for the development of psychotic disorders, it is also conceptualised as a clinical syndrome associated with functional impairment.

Aims

To investigate meta-analytically the functional status of patients at high clinical risk for psychosis and its association with longitudinal outcomes.

Method

Three meta-analyses compared level of functioning ($n=3012$) and quality of life (QoL) ($n=945$) between a high-risk group, a healthy control group and group with psychosis, and baseline functioning in people in the high-risk group who did or did not have a transition to psychosis at follow-up ($n=654$).

Results

People at high risk had a large impairment in functioning

($P<0.001$) and worse QoL ($P=0.001$) than the healthy control group, but only small to moderately better functioning ($P=0.012$) and similar QoL ($P=0.958$) compared with the psychosis group. Among the high-risk group, those who did not develop psychosis reported better functioning ($P=0.001$) than those who did.

Conclusions

Our results indicate that the high-risk state is characterised by consistent and large impairments of functioning and reduction in QoL similar to those in other coded psychiatric disorders.

Declaration of interest

None.

Copyright and usage

© The Royal College of Psychiatrists 2015.

The clinical state of high risk of psychosis defines a condition characterised by attenuated psychotic symptoms, brief limited intermittent psychotic episode, genetic vulnerability or the presence of basic symptoms.¹ As the name suggests, these diagnostic criteria were originally developed to identify people at high risk of developing a psychotic disorder over time. Under this conceptualisation the condition would allow detection and treatment of a group at very high risk of developing a severe and full disorder longitudinally. This paradigm would fit the aims of indicated prevention in this group,² who have up to 30% risk of developing psychosis, mostly schizophrenia spectrum disorders,³ within the following 2 years. Accordingly, preventive treatments primarily aim at reducing the risk associated with the condition and thus preventing the outcome.^{4,5} The 'high risk' paradigm does not explicitly require functional impairments as inclusion criteria,⁶ with the exception of the genetic risk and deterioration subgroup, which however is traditionally small. On the other hand, over the past few years a competing paradigm has emerged. The 'attenuated psychosis' syndrome (APS) has been published in DSM-5.^{7,8} The APS construct specifically requires patient distress or disability, which has not explicitly been part of the high-risk concept, although distress and disability are implicit in the symptom severity ratings that are required for the research diagnosis of high risk,⁸ defined as ultra-high risk (so not basic symptoms). In this sense the APS better resembles the clinical condition of angina pectoris, which is *per se* associated with signs and symptoms impairing the quality of life (QoL) and level of functioning of the individual. The APS diagnosis has been relegated to the research appendix of the DSM-5 because of lack of consensus among researchers on the validity of this category

as a syndrome and for the inconclusiveness of data supporting its diagnostic reliability.⁹

One way to partially circumvent this controversial issue is to clarify the functional status of people at high risk at the time of their presentation to prodromal services and independently from their longitudinal outcomes. In fact, according to the DSM criteria,⁷ an impairment of functioning along with significant distress are basic criteria for the conceptual validity of all psychiatric disorders,¹⁰ differentiating a physiological trait or asymptomatic risk factor from a disorder and determining the patient's need for treatment: 'mental disorders are usually associated with significant distress in social, occupational, or other important activities.'⁷ A number of studies investigating functioning or QoL in people at high risk have been published in recent years. Surprisingly, to date no quantitative synthesis has been published regarding the functioning and QoL of such people when they are seeking help from prodromal clinics. The results are particularly controversial when people at high risk are compared with patients with established psychosis.^{11–14}

Our first aim was to investigate validity of the high-risk state by addressing consistency and magnitude of baseline functioning and QoL in high-risk individuals compared with a healthy control group and people with a frank diagnosis of psychosis. We additionally investigated the impact of baseline difference in high-risk functioning on the longitudinal development of psychotic disorders.

Method

The main research hypothesis and the study protocol were decided *a priori*. We used a systematic search strategy to identify relevant articles. Two investigators (A.S. and A.A.) conducted a two-step

*Joint first authors.

literature search. As a first step the Web of Knowledge database (Thomson Reuters) was searched, incorporating both the Web of Science and Medline. The search was extended until December 2013, including abstracts in English language only. The electronic research adopted several combinations of the following keywords: “at risk mental state”, “psychosis risk”, “prodrome”, “prodromal psychosis”, “ultra high risk”, “functioning”, “quality of life” and name of the possible assessment instruments (see online supplement DS1 for details). The second step involved the implementation of an additional electronic search based on a manual search of the reference lists of the retrieved articles. Abstracts of articles identified through these two steps were then screened for the selection criteria, and articles surviving this screening were assessed for eligibility on the basis of a full-text reading. Discrepancies were resolved through consensus with a third author (M.R.). To achieve a high standard of reporting we adopted the Meta-analysis of Observational Studies in Epidemiology (MOOSE) checklist.¹⁵

Selection criteria

Inclusion criteria for the first two meta-analyses, focusing on the difference between the groups in functioning (meta-analysis 1) and QoL (meta-analysis 2), were as follows:

- (a) original article, written in English;
- (b) inclusion of a sample at high risk (i.e. presence of attenuated psychosis symptoms, genetic risk and deterioration, brief limited and intermittent psychotic episode, basic symptoms) according to international standard definition;¹
- (c) inclusion of a comparison group of healthy participants or patients with psychosis;
- (d) cross-sectional study, cohort study or descriptive study reporting sufficient meta-analytical data on functioning.

Meta-analysis 3 focused on the difference in functioning between high-risk participants who made (HR-T) or did not make (HR-NT) a transition to psychosis at follow-up in descriptive longitudinal studies. Inclusion criteria (a) and (b) were the same as above, with an additional criterion that the article reported baseline data on functioning together with the longitudinal transition outcome at follow-up. Exclusion criteria were common to all analyses: articles were excluded if they were abstracts, pilot data-sets or reviews, failed to report enough data for meta-analysis or had overlapping data-sets. Specifically, in case of multiple publications deriving from the same study population, we selected the article reporting the largest and most recent data-set.

Recorded variables

Data extraction and quality assessment were independently performed by two investigators (A.S. and A.A.). Inconsistency and disagreements on quality rating were double-checked and resolved with a third author (M.R.). The following variables were recorded from each article: author, year of publication, quality criterion (see below), comparison group type (healthy participants or patients with established psychosis), epidemiological data of high-risk and control samples (baseline sample sizes, mean age, proportion of females), the high-risk diagnostic instrument adopted, the instrument employed to assess functioning and the level of functioning. The last variable was the primary outcome measure for the first meta-analysis. The following data on functioning were extracted: mean value and standard deviation of the mean in both the high-risk and comparison groups, direction of the difference and level of significance of the difference.¹⁶ We additionally extracted data on QoL as defined by the mean of different psychometric instruments and used it as secondary outcome measure. If

the data were reported for subgroups we merged the values (online Table DS1). For meta-analysis 3 we extracted baseline functioning in the HR-T and HR-NT groups as the primary outcome. Demographic data, publication year and duration of follow-up (months) were extracted finally to assess their putative moderator effect.

Quality assessment

Although quality assessments can be reliably conducted in meta-analyses of experimental studies their use in observational research is controversial, with no clear consensus on rating methods or their appropriate use in the analysis.¹⁷ We adapted the Newcastle–Ottawa Scale for the evaluation of non-randomised studies (www.ohri.ca/programs/clinical_epidemiology/oxford.asp). The scale evaluates the quality of observational studies, allocating a maximum of nine stars for the highest quality. This tool has been adopted in recent meta-analyses.¹⁸

Statistical analysis

We performed three meta-analyses using Comprehensive Meta-Analysis Software version 2.¹⁹ When the same outcome was evaluated within the same study with more than one scale we retained just one measure according to a predefined order (see Method in online supplement DS1). As a measure of effect size in meta-analyses 1 and 2 Hedges’ *g* was adopted, i.e. the difference between the functioning (or QoL) means of the comparison and high-risk groups, divided by the standard deviation and weighted for sample size, to correct for bias from small sample sizes. In meta-analysis 3 Hedges’ *g* was employed to test differences in functioning between the HR-T and HR-NT groups. The influence of putative continuous moderators (year of publication, demographic variables, length of follow-up) was tested using meta-regression analyses, dividing the significance level ($P=0.05$, two-tailed) by number of moderators tested to adjust for multiple comparisons. The slope of meta-regression line – β coefficient: direct (+) or inverse (–) – indicates the strength of the relationship between moderator and outcome. Meta-regressions were performed when at least ten studies were available for the preselected outcome of interest. We additionally performed a supplementary analysis using the cross-sectional studies employing the Global Assessment of Functioning (GAF). Furthermore, since the most recent studies adopting the Comprehensive Assessment of At-Risk Mental States (CAARMS) for high-risk state included functioning as a diagnostic criterion,⁹ a subgroup analysis was performed to control for this possible confounder. Further methodological details are available in online supplement DS1.

Heterogeneity, publication bias and sensitivity

Heterogeneity among study point estimates was assessed using *Q* statistics,²⁰ with the proportion of the total variability in the effect size estimates being evaluated with the I^2 index.²¹ As meta-analysis of observational studies is supposed to be characterised by significant heterogeneity, random effect models were used. In general, random effect models are more conservative than fixed effect models, and appear to better address heterogeneity between studies and study populations, allowing for greater flexibility in parsing effect size variability. Moreover, they are less influenced by extreme variations in sample size.²² The possibility of a publication bias in our study was tested with the Duval & Tweedie trim and fill method.²³ This method imputes values estimated to be missing from the analysis (e.g. for publication bias) and re-estimates the effect size. If the conclusion of the meta-analysis remains unchanged following the trim and fill adjustment the results can be considered as robust. To further assess the robustness

of the results, we performed sensitivity analyses by sequentially removing each study and rerunning all three meta-analyses. We also conducted a second sensitivity analysis for meta-analysis 2 excluding studies with quality ratings in the lowest quartile, to determine whether potential methodological weaknesses influenced meta-analytic estimates.

Results

For meta-analyses 1 and 2 electronic and manual search uncovered 1168 potential abstracts. After the first screening through abstract reading 226 full-text articles were downloaded for selection, of which 30 met the inclusion criteria as they were comparing functioning or QoL between high-risk participants and comparisons, accounting for a total of 3608 participants (meta-analysis 1: $n=3012$, mean age 20.7 years, 38.8% female; meta-analysis 2: $n=945$, mean age 23.7 years, 41.4% female; online Fig. DS1 (a) and (b)). There were no studies employing basic symptom criteria in the final database. For meta-analysis 3, electronic and manual search uncovered 1181 potential abstracts. After the first screening through abstract reading 244 full-text articles were downloaded for selection; of these, 10 longitudinal studies reporting baseline functioning in the transition and non-transition groups were eventually included (mean length of follow-up 28.3 months, $n=654$; mean age at baseline 19.1 years, 43.5% female; online Fig. DS1 (c)). The details of the final database are reported in online Table DS2.

Functioning in high-risk individuals

Comparison with healthy control group

There was a large and significant impairment in functioning across the high-risk group compared with the healthy control group, with small 95% confidence intervals indicating the precision of the estimate (Hedges' $g=-3.01$, 95% CI -3.68 to -2.34 , $P<0.001$, $n=18$; Fig. 1(a)). The Duval & Tweedie trim and fill procedures found no missing study (random model applied), suggesting absence of publication bias. There was considerable heterogeneity across the included studies ($Q=497.4$, $I^2=96.6\%$, d.f. = 17, $P<0.001$) but the direction of the effect was consistent and significant for each study. No study accounted for more than 5.9% of the overall effect size. Meta-regression analysis adjusted for multiple comparison found that a proportion of females in the healthy control group was correlated with the magnitude of the effect size ($\beta=-2.61$, 95% CI -3.75 to -1.48 , $P<0.001$, $Q=20.5$, $n=15$). Conversely, there was no association between level of functioning and high-risk gender, high-risk or healthy control group age or publication year. The sensitivity analysis computing after removing each study and the studies in the lower quartile of quality rating confirmed our findings with no significant change.

Comparison with the psychosis group

People in the high-risk group were less impaired on functional status than patients with frank psychosis. The magnitude of this effect was small to moderate (Hedges' $g=0.34$, 95% CI 0.07 to 0.60, $P=0.012$, $n=14$; Fig. 1(b)), with large confidence intervals indicating imprecision. There was no publication bias. There was significant heterogeneity across studies ($Q=63.3$, $I^2=79.5\%$, d.f. = 13, $P<0.001$). Meta-regression analyses adjusted for multiple comparisons revealed better functioning in women in both high-risk ($\beta=-1.76$, 95% CI -3.03 to -0.49 , $P=0.007$, $Q=7.4$, $n=14$) and psychosis group ($\beta=-2.43$, 95% CI -3.61 to -1.25 , $P<0.001$, $Q=16.3$, $n=14$) comparisons (online Fig.

DS2). Conversely, there was no association in either group with age or with publication year. These results were confirmed by sensitivity analyses. Results of the supplementary analyses investigating the mean GAF scores of the three comparison groups, and the possible effect of the high-risk diagnostic tool (i.e. CAARMS *v.* Structured Interview for Prodromal Symptoms, SIPS), are reported online (Figs DS3 and DS4).

Quality of life

Meta-analysis 2 showed that the high-risk group had poorer QoL than the healthy control group (Hedges' $g=-1.75$, 95% CI -2.83 to -0.67 , $P=0.001$, $n=4$; Fig. 2(a)). Furthermore, we found no difference in QoL between the high-risk and psychosis groups (Hedges' $g=0.02$, 95% CI -0.64 to 0.67, $P=0.958$, $n=3$; Fig. 2(b)). The heterogeneity in the subgroup analysis was considerable (high-risk *v.* healthy control group: $Q=91.8$, $I^2=96.7\%$, d.f. = 3, $P<0.001$; high-risk *v.* psychosis group: $Q=16.1$, $I^2=87.6\%$, d.f. = 2, $P<0.001$); however, given the small number of studies, we did not perform meta-regression analyses. The sensitivity analysis computing after removing each study confirmed our findings, with no significant change.

Functioning and psychosis transition

There was meta-analytical difference in baseline level of functioning between the HR-T and HR-NT groups (mean follow-up 28.9 months, s.d. = 16.0). The magnitude of the effect was moderate, with those in the HR-T group showing poorer baseline functioning than the HR-NT group (Hedges' $g=0.43$, 95% CI 0.17 to 0.68, $P=0.001$, $n=10$; Fig. 3). The trim and fill procedure showed that the result was robust against publication bias. The heterogeneity between studies was moderate ($Q=20.0$, $I^2=54.9\%$, d.f. = 9, $P=0.018$). Meta-regressions adjusted for multiple comparisons revealed a significant correlation with publication year ($\beta=-0.10$, 95% CI -0.17 to -0.03 , $P=0.005$, $Q=7.8$, $n=10$), but no association with length of follow-up ($P=0.121$), gender of participants ($P=0.651$) or age ($P=0.254$). The sensitivity analysis computing after removing each study confirmed our findings with no significant change.

Discussion

People at high risk of psychosis (defined on the basis of ultra-high risk criteria) had a statistically significant impairment in global functioning that was very large compared with a healthy control group, but only small to moderate when compared with patients with psychosis. Within the high-risk group, lower baseline level of global functioning predicted the later onset of psychosis. Impairments of QoL in the high-risk group were similar to those observed in the psychosis group. The results were robust and not affected by publication bias.

The results of our meta-analysis are important for research and clinicians working in the field of psychosis prevention because there is no consensus with respect to the functional status of people at high risk of psychosis. For example, some authors argue that such people are not at all dysfunctional, as their signs and symptoms represent 'normal developmental processes' or expressions of psychosis vulnerability that are common in the general population.²⁴ These authors also suggested that help-seeking is only a behaviour not suggestive of functional impairments and questioned whether these individuals actually need treatment,²⁴ concluding that 'it is not appropriate to treat high-risk people before the psychosis onset.'²⁵ To our knowledge this is the first ever meta-analysis clearly addressing these




Fig. 1 Functional impairment: forest plots of meta-analysis 1. The large effect size of the subgroup analysis indicated (a) lower functioning of the high-risk group *v.* the healthy control group and (b) a moderate standardised difference in functioning between the high-risk group and the psychosis group.

GAF, Global Assessment of Functioning; GF-social, Global Functioning – social scale; HR, high risk; SOFAS, Social and Occupational Functioning Assessment Scale; SFS, Social Functioning Scale.

speculations and investigating the functional status of high-risk participants compared with healthy control and psychosis groups.

Functional impairment

We clearly found that functioning of people at high risk was strongly impaired compared with the healthy control group but only modestly impaired compared with people with psychosis. These impairments may have been present for a long period prior to referral to high-risk services.²⁶ Our supplementary analysis focusing only on studies employing the GAF indicated a mean score of about 79 for the healthy control group, 50 for the high-

risk group and 45 for the psychosis group. This pattern suggests that the functional level in people at high risk is closer to that observed in people with psychosis as opposed to that observed in healthy individuals. This pattern is further supported by the meta-analysis of the QoL, which found no significant difference between the high-risk and psychosis groups and again a significant reduction in QoL compared with the healthy control group. It is relevant that functional impairment as well as QoL reported for the high-risk group was observed at the initial assessment in early detection centres before any focused intervention was initiated. Impairments in functioning and QoL are therefore a key feature of the high-risk state, at least as defined with the ultra-high risk




Fig. 2 Quality of life: forest plots of meta-analysis 2. The subgroup analysis indicated that quality of life of the high-risk group was worse than that of the healthy control group (a) but similar to that of the psychosis group (b).

HR, high risk; MANSA, Manchester Short Assessment of Quality of Life; MSQoL, Modular System for Quality of Life; QLS, Quality of Life Scale.

criteria (we found no basic symptom studies eligible for the current meta-analysis). Since QoL in the high-risk group was similar to that observed in patients with psychosis, it is possible to argue that severe functional impairment may lead to self-stigmatising by high-risk patients independently of any diagnostic label.²⁷ To better understand the magnitude of the functional impairment of the high-risk state, it can be qualitatively compared with that of other psychiatric disorders (Fig. 4).

Although such a comparison should be interpreted cautiously as it is not based on original data, on a qualitative basis the graph indicates that the point estimate of the global functioning in the high-risk group is lower than those observed in bipolar disorder, and similar to that of major depressive disorders and social phobia. This is the first meta-analytical evidence that high-risk individuals are 'probably at risk but certainly ill', as previously advocated.²⁸

The findings of large functional impairments in the high-risk group clearly contradict the speculative assumption that they represent normal developmental phenotypes and are not in need of care. Conversely, in synopsis of the results of the meta-analyses and the qualitative placement of the observed GAF scores shown in Fig. 4, it seems strongly justifiable to conclude that the functional state observed in those meeting high-risk criteria calls not only for prevention of a future transition to psychosis, but also for treatment of the current mental state and problems.

Comorbidity

It may be argued that functional impairment in those at high risk of psychosis is secondary to comorbid disorders diagnosed in this group. There is evidence that affective comorbidities are highly




Fig. 3 Baseline functional impairment and transition to psychosis: forest plot of meta-analysis 3. Participants at high risk who developed psychosis during the follow-up period had poorer baseline functioning than participants who did not.

GAF, Global Assessment of Functioning; HR-NT, high risk, no transition to psychosis; HR-T, high risk, transition to psychosis; SOFAS, Social and Occupational Functioning Assessment Scale.




Fig. 4 Qualitative comparison of Global Assessment of Functioning (GAF) scores in different psychiatric conditions.

The plot displays the result of our supplementary meta-analysis of GAF point estimates for the high-risk group (defined with ultra-high risk criteria), the healthy control group and the psychosis group, which has been qualitatively compared with GAF estimates in bipolar disorder (taken from Hajek *et al.*), major depressive disorder (from Schaub *et al.*), body dysmorphic disorder (from Phillips *et al.*) and social phobia (from Kelly *et al.*).^{52–55} The dashed line represents the high-risk group mean GAF score, to facilitate visual comparison.

prevalent in these individuals,²⁹ affecting psychopathology, neurobiology and baseline functioning.^{30,31} However, in an earlier meta-analysis we found comorbid affective disorders to be present in less than half of the high-risk group (comorbid depressive disorder 41%, anxiety disorder 15%).³⁰ Consequently, the functional and QoL impairment observed in the high-risk group could not entirely be secondary to the presence of affective comorbidities. The European Prediction of Psychosis (EPOS) study estimated the impact of both high-risk and depressive psychopathology on baseline GAF scores, using the Beck Depression Inventory and the SIPS as independent variables; step-wise linear regression retained SIPS-positive and SIPS-negative scores only, explaining 14.9% of variance and thus indicating that GAF scores were predominantly determined by deterioration of role functioning.³² On the other hand, even if comorbid symptoms fulfilling the thresholds for certain DSM or ICD disorders had an impact on the GAF ratings, these scores could be interpreted as a true expression of the high-risk state: such comorbid symptoms could well be considered as part of the high-risk state, in line with retrospective findings indicating that prevalence of depressive mood at the time of psychosis onset is 83%,³³ and with phenomenological evidence of affective dysregulation at the core of psychosis liability.³⁴ Affective symptoms may thus be part of the high-risk state and might be expression of an early, mild stage of the same neurobiological process that causes psychosis.³³

Specificity and sensitivity

We also supported the notion that functional impairment may help in enriching the risk (specificity) of high-risk samples.³⁵ In fact, as compared with ultra-high-risk individuals,³⁶ short-term transition risk in individuals with psychotic-like symptoms but good functioning is extremely low (about 1.2% within 2 years).³⁷ However, it is possible that rigorous functioning criteria might enrich the high-risk sample but at the cost of sensitivity. Another study investigating the prevalence of high-risk symptoms in a

community sample aged 11–13 years found the proportion of participants meeting CAARMS high-risk criteria declined from 7.7% to 0.9% when a 30% decrease of functioning was considered a criterion.³⁸ Thus, at least at the population level, adding this functioning criterion may lead to an immense loss of sensitivity. A corresponding finding was reported from the Personal Assessment and Crisis Evaluation (PACE) 400 study.³⁹ It has still to be elucidated in longitudinal follow-up studies whether there is a criterion leading to a better balance of sensitivity and specificity; however, risk stratification might overcome this problem.³² Furthermore, even without transition to psychosis, functional decline may constitute an outcome of the high-risk state with a comparable clinical significance. Thus, besides a loss of sensitivity, defining impaired functioning as an obligatory entry criterion for high-risk status may result in missing the main goal of prevention, i.e. lowering the huge personal and socioeconomic burden of the disease related to impaired functioning.⁴⁰ Future studies may therefore have to find a balance between sufficient risk enrichment in terms of transition to psychosis and sufficient sensitivity in terms of functional outcome.

The need for care

Besides these speculations, our meta-analysis provides conclusive and consistent evidence that people at high risk are truly in need of care. Our analysis found no evidence of publication bias, and all the sensitivity analyses performed confirmed our findings. We investigated factors modulating functional level in high-risk participants. A small proportion of the observed heterogeneity was explained by gender, suggesting better functional level in women with psychosis. Such a result is in line with available studies in the psychosis spectrum disorders reporting higher functional levels in women than in men.⁴¹

Our longitudinal meta-analysis revealed that high-risk individuals who later developed psychosis had poorer functioning at baseline. This finding is not new,⁴² and is in line with the significant predictive value of high-risk functional impairment

towards transition that has been reported in large independent samples.^{32,43–45} Some authors support the idea of high risk as a continuum towards psychosis, marked by a change in functioning and course of thinking.⁴³ These results may have both clinical and research implications. High-risk samples could be stratified at baseline on the basis of their functional level and focused interventions or experimental trials could be individualised accordingly. Additionally, since most high-risk participants received at least in part some active treatment, our longitudinal results are in line with reports of low efficacy of preventive interventions on social functioning in these people.⁵ In this analysis we found a significant modulating effect for year of publication, suggesting that in the most recent studies the difference in functioning between the two transition groups decreased. This can be interpreted as the consequence of changes in recruitment strategies of prodromal clinics, with inclusion of less functionally impaired patients in the most recent years.¹ Overall, when interpreting the impact of baseline functioning on transition outcomes, it is important to note that psychosis is just one possible outcome of the high-risk state; remission, transition to a non-psychotic disorder and persistence of the high-risk state account for the majority of outcomes at follow-up.¹ Our analysis was unable to test the impact of baseline level of functioning on these outcomes. Functional status, on the other hand, could be considered as a good indicator of broader clinical outcome also in patients who will subsequently develop psychosis.^{1,35}

Study limitations

Some limitations need to be acknowledged. First, the concept of functional impairment had some intrinsic conceptual caveats. Most of the scales adopted, especially the GAF, do not provide a clear distinction between functioning and symptoms.⁴⁶ However, the vast majority of studies of the high-risk state published to date have used the GAF as a standard measure of functioning. The Social and Occupational Functioning Assessment Scale (SOFAS) has been developed to overcome this issue. Unlike the GAF, which includes not only social and occupational performance but also symptoms as a dimension of functioning, the SOFAS aims to assess functioning without the influence of the patient's symptoms.⁴⁷ However, both scales have strong negative correlations with the Clinical Global Impression and the Positive and Negative Syndrome Scale.⁴⁷ Further development in the field may imply the use of psychometric instruments powered to disentangle these two overlapping domains. Another limitation is that we did not attempt to acquire unpublished data. Yet another is that in both subgroup analyses a large part of the heterogeneity remained unexplained. Differences in sampling procedures and assessment measures could be some of the putative moderators that further studies need to take into account to increase the generalisability of findings. Also, the quality of the studies included may have affected interpretation of the results: only half of the studies used a matched (i.e. at least by age) comparison group (see online Table DS3). Another potential limitation is that the researchers assessing functioning and QoL were masked to case-comparison allocation in only a minority of studies. However, our sensitivity analysis showed no effect of quality of studies on the meta-analytical estimates. Furthermore, given conceptual and pragmatic differences between the high-risk and DSM-5 paradigms,⁶ and given the lack of generalisability of high-risk research to the general population,⁴⁸ our findings cannot be directly used to support the validity of the APS diagnosis. Our results support conceptual validity of the high-risk state, i.e. correctly distinguishing between disorder and normality,⁴⁹ rather than its construct validity. Conversely, DSM-5 criteria for a mental

disorder focus on construct validity, requiring that the disorder in question is distinct from other disorders, has familial aggregation, presence in diverse populations and environmental risk factors, has concurrent validators such as cognitive and temperament correlates, biological markers and a certain comorbidity profile, and has predictive validity with respect to diagnostic stability, predictability of the course of illness, and response to treatment.⁵⁰ Conceptual and construct validity are independent.⁴⁹ Although the high-risk state may encompass different comorbid disorders,^{30,31} and thus lack full construct validity, it can be conceptually valid since it encompasses only disorders. However, the same arguments can be used to question construct validity of affective disorders, given their high co-occurrence during first episodes of psychosis.³³ Indeed, satisfying construct validity has as yet not been achieved even for many other hitherto encoded mental disorders. A full discussion of these issues is beyond the scope of the current investigations and has been critically presented in other recent papers.^{6,51}

Clinical implications

The high-risk state (defined with ultra-high risk criteria) is characterised by consistent and serious impairments of functioning and reduction of QoL that seem to be similar to those in other coded psychiatric disorders. These impairments call not only for prevention of a future transition to psychosis and functional deterioration, but also for treatment of the current disorder.

Paolo Fusar-Poli, PhD, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, and Outreach and Support in South London (OASIS) prodromal team, South London and the Maudsley National Health Service (NHS) Foundation Trust, London; **Matteo Rocchetti**, MD, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK, and Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy; **Alberto Sardella**, PsyD, **Alessia Avila**, PsyD, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; **Martina Brandizzi**, MD, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK, and Neurosciences, Mental Health and Sensory Functions Department, Sapienza University of Rome, Rome, Italy; **Edgardo Caverzasi**, Professor, **Pierluigi Politi**, Professor, Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; **Stephan Ruhrmann**, PhD, Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany; **Philip McGuire**, Professor, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, and OASIS prodromal team, South London and the Maudsley NHS Foundation Trust, London, UK

Correspondence: Dr Paolo Fusar-Poli, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, PO Box 63, De Crespigny Park, London SE5 8AF, UK. Email: paolo.fusar-poli@kcl.ac.uk

First received 4 Sep 2014, final revision 24 Nov 2014, accepted 17 Dec 2014

Funding

This work was supported by the Department of Psychosis Studies, King's College London, Institute of Psychiatry, Psychology and Neuroscience. M.R., E.C. and P.P. were also supported by the University of Pavia; M.B. was also supported by the Sapienza University of Rome.

References

- 1 Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultz-Lutter F, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. *JAMA Psychiatry* 2013; **70**: 107–20.
- 2 Mrazek PB, Haggerty RJ, eds. *Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research*. National Academies Press, 1994.
- 3 Fusar-Poli P, Bechdolf A, Taylor MJ, Bonoldi I, Carpenter WT, Yung AR, et al. At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. *Schizophr Bull* 2013; **39**: 923–32.
- 4 Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T. Early interventions to prevent psychosis: systematic review and meta-analysis. *BMJ* 2013; **346**: f185.

- 5 Van der Gaag M, Smit F, Bechdolf A, French P, Linszen DH, Yung AR, et al. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. *Schizophr Res* 2013; **149**: 56–62.
- 6 Fusar-Poli P, Carpenter WT, Woods SW, McGlashan TH. Attenuated psychosis syndrome: ready for DSM-5.1? *Annu Rev Clin Psychol* 2014; **10**: 155–92.
- 7 American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (5th edn) (DSM-5)*. APA, 2013.
- 8 Woods SW, Walsh BC, Saksa JR, McGlashan TH. The case for including attenuated psychotic symptoms syndrome in DSM-5 as a psychosis risk syndrome. *Schizophr Res* 2010; **123**: 199–207.
- 9 Schultze-Lutter F, Schimmelmann BG, Ruhrmann S, Michel C. 'A rose is a rose is a rose', but at-risk criteria differ. *Psychopathology* 2013; **46**: 75–87.
- 10 Blumenthal-Barby JS. Psychiatrist's new manual (DSM-5): ethical and conceptual dimensions. *J Med Ethics* 2014; **40**: 531–6.
- 11 Addington J, Penn D, Woods SW, Addington D, Perkins DO. Social functioning in individuals at clinical high risk for psychosis. *Schizophr Res* 2008; **99**: 119–24.
- 12 Simon AE, Graedel M, Cattapan-Ludewig K, Gruber K, Ballinari P, Roth B, et al. Cognitive functioning in at-risk mental states for psychosis and 2-year clinical outcome. *Schizophr Res* 2012; **142**: 108–15.
- 13 Ruhrmann S, Paruch J, Bechdolf A, Pukrop R, Wagner M, Berning J, et al. Reduced subjective quality of life in persons at risk for psychosis. *Acta Psychiatr Scand* 2008; **117**: 357–68.
- 14 Ruhrmann S, Paruch J, Bechdolf A, Pukrop R, Wagner M, Berning J, et al. Reduced subjective quality of life in persons at risk for psychosis. *Acta Psychiatr Scand* 2008; **117**: 357–68.
- 15 Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000; **283**: 2008–12.
- 16 Rosenthal R. Meta-analysis: a review. *Psychosom Med* 1991; **53**: 247–271.
- 17 Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. *JAMA* 1999; **282**: 1054–60.
- 18 Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. *BMJ* 2013; **347**: f5061.
- 19 Borenstein M, Hedges L, Higgins J, Rothstein H. *Comprehensive Meta-Analysis Version 2*. Biostat, 2005.
- 20 Paulson JF, Bazemore SD. Prenatal and postpartum depression in fathers and its association with maternal depression: a meta-analysis. *JAMA* 2010; **303**: 1961–9.
- 21 Lipsey M, Wilson D. *Practical Meta-analysis*. Sage, 2000.
- 22 Cooper H, Hedges L, Valentine J. *Handbook of Research Synthesis and Meta-Analysis*. Sage, 2009.
- 23 Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000; **56**: 455–63.
- 24 Castle DJ. The truth, and nothing but the truth, about early intervention in psychosis. *Aust N Z J Psychiatry* 2012; **46**: 10–3.
- 25 Castle DJ. Is it appropriate to treat people at high-risk of psychosis before first onset? – no. *Med J Australia* 2012; **196**: 557.
- 26 Fusar-Poli P, Meneghelli A, Valmaggia L, Allen P, Galvan F, McGuire P, et al. Duration of untreated prodromal symptoms and 12-month functional outcome of individuals at risk of psychosis. *Br J Psychiatry* 2009; **194**: 181–2.
- 27 Ruhrmann S, Klosterkötter J, Bodatsch M, Nikolaidis A, Julkowski D, Hilboll D, et al. Chances and risks of predicting psychosis. *Eur Arch Psychiatry Clin Neurosci* 2012; **262** (suppl 2): S85–90.
- 28 Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Probably at-risk, but certainly ill – advocating the introduction of a psychosis spectrum disorder in DSM-V. *Schizophr Res* 2010; **120**: 23–37.
- 29 Salokangas RK, Ruhrmann S, von Reventlow HG, Heinimaa M, Svriskis T, From T, et al. Axis I diagnoses and transition to psychosis in clinical high-risk patients EPOS project: prospective follow-up of 245 clinical high-risk outpatients in four countries. *Schizophr Res* 2012; **138**: 192–7.
- 30 Fusar-Poli P, Nelson B, Valmaggia L, Yung AR, McGuire PK. Comorbidity depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. *Schizophr Bull* 2014; **40**: 120–31.
- 31 Modinos G, Allen P, Frascarelli M, Tognin S, Valmaggia L, Xenaki L, et al. Are we really mapping psychosis risk? Neuroanatomical signature of affective disorders in subjects at ultra high risk. *Psychol Med* 2014; **44**: 3491–501.
- 32 Ruhrmann S, Schultze-Lutter F, Salokangas RKR, Heinimaa M, Linszen D, Dingemans P, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. *Arch Gen Psychiatry* 2010; **67**: 241–51.
- 33 Hafner H, Maurer K, Trendler G, an der Heiden W, Schmidt M, Konnecke R. Schizophrenia and depression: challenging the paradigm of two separate diseases – a controlled study of schizophrenia, depression and healthy controls. *Schizophr Res* 2005; **77**: 11–24.
- 34 Mishara AL, Fusar-Poli P. The phenomenology and neurobiology of delusion formation during psychosis onset: Jaspers, Truman symptoms, and aberrant salience. *Schizophr Bull* 2013; **39**: 278–86.
- 35 Fusar-Poli P, Van Os J. Lost in transition: setting the psychosis threshold in prodromal research. *Acta Psychiatr Scand* 2013; **127**: 248–52.
- 36 Kempton MJ, Bonoldi I, Valmaggia L, McGuire P, Fusar-Poli P. Speed of psychosis progression in people at ultra-high clinical risk: a complementary meta-analysis. *JAMA Psychiatry* 2015; **72**: 622–3.
- 37 Kaymaz N, Drukker M, Lieb R, Wittchen HU, Werbeloff N, Weiser M, et al. Do subthreshold psychotic experiences predict clinical outcomes in unselected non-help-seeking population-based samples? A systematic review and meta-analysis, enriched with new results. *Psychol Med* 2012; **42**: 2239–53.
- 38 Kelleher I, Murtagh A, Molloy C, Roddy S, Clarke MC, Harley M, et al. Identification and characterization of prodromal risk syndromes in young adolescents in the community: a population-based clinical interview study. *Schizophr Bull* 2012; **38**: 239–46.
- 39 Nelson B, Yuen HP, Wood SJ, Lin A, Spiliotacopoulos D, Bruxner A, et al. Long-term follow-up of a group at ultra high risk ('prodromal') for psychosis: the PACE 400 study. *JAMA Psychiatry* 2013; **70**: 793–802.
- 40 Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. *Eur Neuropsychopharmacol* 2011; **21**: 718–79.
- 41 Grossman LS, Harrow M, Rosen C, Faull R. Sex differences in outcome and recovery for schizophrenia and other psychotic and nonpsychotic disorders. *Psychiatr Serv* 2006; **57**: 844–50.
- 42 Velthorst E, Nelson B, Wiltink S, de Haan L, Wood SJ, Lin A, et al. Transition to first episode psychosis in ultra high risk populations: does baseline functioning hold the key? *Schizophr Res* 2013; **143**: 132–7.
- 43 Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, et al. Prediction of psychosis in youth at high clinical risk. *Arch Gen Psychiatry* 2008; **65**: 28–37.
- 44 Velthorst E, Nieman DH, Linszen D, Becker H, de Haan L, Dingemans PM, et al. Disability in people clinically at high risk of psychosis. *Br J Psychiatry* 2010; **197**: 278–84.
- 45 Thompson A, Nelson B, Yung A. Predictive validity of clinical variables in the 'at risk' for psychosis population: international comparison with results from the North American Prodrome Longitudinal Study. *Schizophr Res* 2011; **126**: 51–7.
- 46 Ustun B, Kennedy C. What is 'functional impairment'? Disentangling disability from clinical significance. *World Psychiatry* 2009; **8**: 82–5.
- 47 Samara MT, Engel RR, Millier A, Kandenwein J, Toumi M, Leucht S. Equipercile linking of scales measuring functioning and symptoms: examining the GAF, SOFAS, CGI-S, and PANSS. *Eur Neuropsychopharmacol* 2014; **24**: 1767–72.
- 48 Schultze-Lutter F, Michel C, Ruhrmann S, Schimmelmann BG. Prevalence and clinical significance of DSM-5 attenuated psychosis syndrome in adolescents and young adults in the general population: the Bern Epidemiological At-Risk (BEAR) Study. *Schizophr Bull* 2014; **40**: 1499–508.
- 49 Wakefield JC. Wittgenstein's nightmare: why the RDoC grid needs a conceptual dimension. *World Psychiatry* 2014; **13**: 38–40.
- 50 Epperson CN, Steiner M, Hartlage SA, Eriksson E, Schmidt PJ, Jones I, et al. Premenstrual dysphoric disorder: evidence for a new category for DSM-5. *Am J Psychiatry* 2012; **169**: 465–75.
- 51 Wakefield JC. The DSM-5 debate over the bereavement exclusion: psychiatric diagnosis and the future of empirically supported treatment. *Clin Psychol Rev* 2013; **33**: 825–45.
- 52 Hajek T, Slaney C, Garnham J, Ruzickova M, Passmore M, Alda M. Clinical correlates of current level of functioning in primary care-treated bipolar patients. *Bipolar Disord* 2005; **7**: 286–91.
- 53 Schaub A, Neubauer N, Mueser KT, Engel R, Moller HJ. Neuropsychological functioning in inpatients with major depression or schizophrenia. *BMC Psychiatry* 2013; **13**: 203.
- 54 Phillips KA, Quinn G, Stout RL. Functional impairment in body dysmorphic disorder: a prospective, follow-up study. *J Psychiatr Res* 2008; **42**: 701–7.
- 55 Kelly MM, Dalrymple K, Zimmerman M, Phillips KA. A comparison study of body dysmorphic disorder versus social phobia. *Psychiatr Res* 2013; **205**: 109–16.

- 56 Carrion RE, Goldberg TE, McLaughlin D, Auther AM, Correll CU, Cornblatt BA. Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis. *Am J Psychiatry* 2011; **168**: 806–13.
- 57 Chudleigh C, Naismith SL, Blaszczyński A, Hermens DF, Hodge MA, Hickie IB. How does social functioning in the early stages of psychosis relate to depression and social anxiety? *Early Interv Psychiatry* 2011; **5**: 224–32.
- 58 Chung YS, Kang D-H, Shin NY, Yoo SY, Kwon JS. Deficit of theory of mind in individuals at ultra-high-risk for schizophrenia. *Schizophr Res* 2008; **99**: 111–8.
- 59 Hui C, Morcillo C, Russo DA, Stochl J, Shelley GF, Painter M, et al. Psychiatric morbidity, functioning and quality of life in young people at clinical high risk for psychosis. *Schizophr Res* 2013; **148**: 175–80.
- 60 Koren D, Reznik N, Adres M, Scheyer R, Apter A, Steinberg T, et al. Disturbances of basic self and prodromal symptoms among non-psychotic help-seeking adolescents. *Psychol Med* 2013; **43**: 1365–76.
- 61 Lindgren M, Manninen M, Laajasalo T, Mustonen U, Kalska H, Suvisaari J, et al. The relationship between psychotic-like symptoms and neurocognitive performance in a general adolescent psychiatric sample. *Schizophr Res* 2010; **123**: 77–85.
- 62 Niendam TA, Berzak J, Cannon TD, Bearden CE. Obsessive compulsive symptoms in the psychosis prodrome: correlates of clinical and functional outcome. *Schizophr Res* 2009; **108**: 170–5.
- 63 Schlosser DA, Jacobson S, Chen Q, Sugar CA, Niendam TA, Li G, et al. Recovery from an at-risk state: clinical and functional outcomes of putatively prodromal youth who do not develop psychosis. *Schizophr Bull* 2012; **38**: 1225–33.
- 64 Serrani D. Neurocognitive assessment of ultra high risk of psychosis states using the MATRICS battery (Measurement and Treatment Research to Improve Cognition in Schizophrenia). *Rev Psiquiatr Clin* 2011; **38**: 130–4.
- 65 Shin YS, Kim SN, Shin NY, Jung WH, Hur JW, Byun MS, et al. Increased intra-individual variability of cognitive processing in subjects at risk mental state and schizophrenia patients. *PLoS One* 2013; **8**: e78354.
- 66 Smieskova R, Fusar-Poli P, Aston J, Simon A, Bendfeldt K, Lenz C, et al. Insular volume abnormalities associated with different transition probabilities to psychosis. *Psychol Med* 2012; **42**: 1613–25.
- 67 Stanford AD, Messinger J, Malaspina D, Corcoran CM. Theory of Mind in patients at clinical high risk for psychosis. *Schizophr Res* 2011; **131**: 11–7.
- 68 Thompson A, Pappas A, Bartholomeusz C, Allott K, Amminger GP, Nelson B, et al. Social cognition in clinical 'at risk' for psychosis and first episode psychosis populations. *Schizophr Res* 2012; **141**: 204–9.
- 69 Van Rijn S, Aleman A, de Sonneville L, Sprong M, Ziermans T, Schothorst P, et al. Misattribution of facial expressions of emotion in adolescents at increased risk of psychosis: the role of inhibitory control. *Psychol Med* 2011; **41**: 499–508.
- 70 Van Tricht MJ, Nieman DH, Koelman JHTM, van der Meer JN, Bour LJ, de Haan L, et al. Reduced parietal P300 amplitude is associated with an increased risk for a first psychotic episode. *Biol Psychiatry* 2010; **68**: 642–8.
- 71 Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. *Schizophr Bull* 2009; **35**: 894–908.
- 72 Eastvold AD, Heaton RK, Cadenhead KS. Neurocognitive deficits in the (putative) prodrome and first episode of psychosis. *Schizophr Res* 2007; **93**: 266–77.
- 73 Fulford D, Niendam TA, Floyd EG, Carter CS, Mathalon DH, Vinogradov S, et al. Symptom dimensions and functional impairment in early psychosis: more to the story than just negative symptoms. *Schizophr Res* 2013; **147**: 125–31.
- 74 Niendam TA, Lesh TA, Yoon J, Westphal AJ, Hutchison N, Daniel Ragland J, et al. Impaired context processing as a potential marker of psychosis risk state. *Psychiatry Res* 2014; **221**: 13–20.
- 75 Pruessner M, Iyer SN, Faridi K, Joober R, Malla AK. Stress and protective factors in individuals at ultra-high risk for psychosis, first episode psychosis and healthy controls. *Schizophr Res* 2011; **129**: 29–35.
- 76 Quednow BB, Frommann I, Berning J, Kuehn KU, Maier W, Wagner M. Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia. *Biol Psychiatry* 2008; **64**: 766–73.
- 77 Rausch F, Eifler S, Esser A, Esslinger C, Schirrmbeck F, Meyer-Lindenberg A, et al. The Early Recognition Inventory ERInas detects at risk mental states of psychosis with high sensitivity. *Compr Psychiatry* 2013; **54**: 1068–76.
- 78 Song YY, Kang JI, Kim SJ, Lee MK, Lee E, An SK. Temperament and character in individuals at ultra-high risk for psychosis and with first-episode schizophrenia: associations with psychopathology, psychosocial functioning, and aspects of psychological health. *Compr Psychiatry* 2013; **54**: 1161–8.
- 79 Washida K, Takeda T, Habara T, Sato S, Oka T, Tanaka M, et al. Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophrenia. *Neuropsychiatr Dis Treat* 2013; **9**: 861–8.
- 80 Kim KR, Song YY, Park JY, Lee EH, Lee M, Lee SY, et al. The relationship between psychosocial functioning and resilience and negative symptoms in individuals at ultra-high risk for psychosis. *Aust N Z J Psychiatry* 2013; **47**: 762–71.
- 81 Bechdolf A, Pukrop R, Kohn D, Tschinkel S, Veith V, Schultze-Lutter F, et al. Subjective quality of life in subjects at risk for a first episode of psychosis: a comparison with first episode schizophrenia patients and healthy controls. *Schizophr Res* 2005; **79**: 137–43.
- 82 Francey SM, Jackson HJ, Phillips LJ, Wood SJ, Yung AR, McGorry PD. Sustained attention in young people at high risk of psychosis does not predict transition to psychosis. *Schizophr Res* 2005; **79**: 127–36.
- 83 Bearden CE, Wu KN, Caplan R, Cannon TD. Thought disorder and communication deviance as predictors of outcome in youth at clinical high risk for psychosis. *J Am Acad Child Adolesc Psychiatry* 2011; **50**: 669–80.
- 84 Bechdolf A, Thompson A, Nelson B, Cotton S, Simmons MB, Amminger GP, et al. Experience of trauma and conversion to psychosis in an ultra-high-risk (prodromal) group. *Acta Psychiatr Scand* 2010; **121**: 377–84.
- 85 Becker HE, Nieman DH, Wiltink S, Dingemans PM, de Fliert JRV, Velthorst E, et al. Neurocognitive functioning before and after the first psychotic episode: does psychosis result in cognitive deterioration? *Psychol Med* 2010; **40**: 1599–606.
- 86 Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, Phillips LJ, et al. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. *Am J Psychiatry* 2005; **162**: 71–8.
- 87 Kim HS, Shin NY, Jang JH, Kim E, Shim G, Park HY, et al. Social cognition and neurocognition as predictors of conversion to psychosis in individuals at ultra-high risk. *Schizophr Res* 2011; **130**: 170–5.
- 88 Koutsouleris N, Davatzikos C, Bottlender R, Patschurek-Kliche K, Scheuerecker J, Decker P, et al. Early recognition and disease prediction in the at-risk mental states for psychosis using neurocognitive pattern classification. *Schizophr Bull* 2012; **38**: 1200–15.
- 89 Lam MML, Hung SF, Chen EYH. Transition to psychosis: 6-month follow-up of a Chinese high-risk group in Hong Kong. *Aust N Z J Psychiatry* 2006; **40**: 414–20.
- 90 Lemos-Giraldez S, Vallina-Fernandez O, Fernandez-Iglesias P, Vallejo-Secco G, Fonseca-Pedrero E, Paino-Pineiro M, et al. Symptomatic and functional outcome in youth at ultra-high risk for psychosis: a longitudinal study. *Schizophr Res* 2009; **115**: 121–9.
- 91 Ziermans TB, Schothorst PF, Sprong M, van Engeland H. Transition and remission in adolescents at ultra-high risk for psychosis. *Schizophr Res* 2011; **126**: 58–64.

